Anlotinib Suppressed Ovarian Cancer Progression via Inducing G2/M Phase Arrest and Apoptosis

Ovarian cancer remains the most common gynecologic malignancy, because of its chemotherapy resistance and relapse. Anlotinib, a new oral multi-targeted tyrosine kinase inhibitor, has shown encouraging antitumor activity in several preclinical and clinical trials, while its effect on ovarian cancer h...

Descripción completa

Detalles Bibliográficos
Autores principales: Zhu, Yanghui, Wang, Xiaoyu, Chen, Zhaoyang, Zhou, Lingyan, Di, Xiangjie, Fan, Ping, He, Zhiyao
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821756/
https://www.ncbi.nlm.nih.gov/pubmed/36614964
http://dx.doi.org/10.3390/jcm12010162

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9821756/
https://www.ncbi.nlm.nih.gov/pubmed/36614964
http://dx.doi.org/10.3390/jcm12010162

Ejemplares similares